Agonist lead identification for the high affinity niacin receptor GPR109a

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 17, 2007, Pages 4914-4919

  Gharbaoui, Tawfik ^a   Skinner, Philip J ^a   Shin, Young Jun ^a   Averbuj, Claudia ^a   Jung, Jae Kyu ^a   Johnson, Benjamin R ^a   Duong, Tracy ^a   Decaire, Marc ^a   Uy, Jane ^a   Cherrier, Martin C ^a   Webb, Peter J ^a   Tamura, Susan Y ^a   Zou, Ning ^a   Rodriguez, Nathalie ^a   Boatman, P Douglas ^a   Sage, Carleton R ^a   Lindstrom, Andrew ^a   Xu, Jerry ^a   Schrader, Thomas O ^a   Smith, Brian M ^a   Chen, Ruoping ^a   Richman, Jeremy G ^a   Connolly, Daniel T ^a   Colletti, Steven L ^b   Tata, James R ^b   Semple, Graeme ^a   more..

^a ARENA PHARMACEUTICALS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Free fatty acids; GPR109a; HM74a; Lead identification; Niacin receptor

Indexed keywords

G PROTEIN COUPLED RECEPTOR; NICOTINIC ACID; PROTEIN GPR109A; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG FORMULATION; DRUG IDENTIFICATION; HUMAN; IN VIVO STUDY; NONHUMAN;

ACIDS, HETEROCYCLIC; ADIPOCYTES; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CYCLIC AMP; DRUG DESIGN; HUMANS; KINETICS; MODELS, CHEMICAL; NIACIN; PYRAZOLES; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; SPLEEN;

EID: 34547547644     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.06.028     Document Type: Article

References (18)

1. Tavintharan S., and Kashyap M.L. Curr. Atheroscler. Rep. 3 (2001) 74
2. Carlson L.A. J. Int. Med. 258 (2005) 94
3. Lorenzen A., Stannek C., Lang H., Andrianov V., Kalvinsh I., and Schwabe U. Mol. Pharmacol. 59 (2001) 349
4. Offermanns S. Trends Pharmacol. Sci. 27 (2006) 384
5. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eilert M., Ignar D.M., Murdock P.R., Steplewski K., Green A., Brown A.J., Dowell S.J., Szekeres P.G., Hassall D.G., Marshall F.H., Wilson S., and Pike N.B. J. Biol. Chem. 278 (2003) 9869
6. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., and Offermanns S. Nat. Med. 9 (2003) 352
7. Tunaru S., Lättig J., Kero J., Krause G., and Offermans S. Mol. Pharmacol. 68 (2005) 1271
8. Semple, G. Niacin Receptor Agonists. MEDI-224, 233rd A.C.S. National Meeting, Chicago, IL, Mar. 25-29, 2007.
9. ® assay from Perkin-Elmer as described by the manufacturer. The cAMP assay was optimized for the appropriate receptor stable clone, 5 μM forskolin was used for stimulation and 50,000 cells were used for each well. Positive controls were defined as cAMP generated by cells without forskolin stimulation and negative controls were defined as cAMP generated by cells with 5 μM forskolin stimulation
10. Lorenzen A., Stannek C., Burmeister A., Kalvinsh I., and Schwabe U. Biochem. Pharmacol. 64 (2002) 645
11. Kupiecki F.P., and Marshall N.B. J. Pharmacol. Exp. Ther. 160 (1968) 166
12. van Herk T., Brussee J., van den Nieuwendijk A.M.C.H., van der Klein P.A.M., Ijzerman A.P., Stannek C., Burmeister A., and Lorenzen A. J. Med. Chem. 46 (2003) 3945
13. Pereira J.N., and Holland G.F. Experientia 23 (1967) 905
14. Jung J.-K., Johnson B.R., Duong T., Decaire M., Uy J., Gharbaoui T., Boatman P.D., Sage C.R., Chen R., Richman J.G., Connolly D.T., and Semple G. J. Med. Chem. 50 (2007) 1445
15. Carlson L.A., Hedbom C., Helgstrand E., Sjöberg B., and Stjernström N.E. Adv. Exp. Med. Biol. 4 (1969) 85
16. Carlson L.A., Hedbom C., Helgstrand E., Sjöberg B., and Stjernström N.E. Acta Pharm. Suec. 9 (1972) 289
17. Seki K., Isegawa J., Fukuda M., and Ohki M. Chem. Pharm. Bull. 32 (1984) 1568
18. Taggart A.K., Kero J., Gan X., Cai T.Q., Cheng K., Ippolito M., Ren N., Kaplan R., Wu K., Wu T.J., Jin L., Liaw C., Chen R., Richman J., Connolly D., Offermanns S., Wright S.D., and Waters M.G. J. Biol. Chem. 280 (2005) 26649